Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., Untch, M., Harbeck, N., Wright, G. S., Bondarenko, I., Glaspy, J., Nowecki, Z., Kayali, F., Chan, A., Levy, C., Liu, M., Kim, S., Lemieux, J., Manikhas, A., Tolaney, S., Lim, E., Gombos, A., Stradella, A., Pegram, M., Fasching, P., Mangel, L., Semiglazov, V., Dieras, V., Gianni, L., Danso, M. A., Vacirca, J., Kroll, S., O'Connell, J., Tang, K., Wei, T., Seidman, A. AMER ASSOC CANCER RESEARCH. 2021

View details for Web of Science ID 000618737700023